PWM
CPRX icon

Provident Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Provident Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,250
Closed -$4K – 107
2020
Q3 		$4K Buy
+1,250
New +$4.89K ﹤0.01% 204

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Provident Wealth Management's CPRX Position: Q4 2020 in Review

Provident Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2020, closing a stake of 1,250 shares — an estimated $4K sold.

Provident Wealth Management first reported a position in CPRX in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

  • Provident Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Provident Wealth Management sold 1,250 Catalyst Pharmaceutical shares in Q4 2020, an estimated $4K.
  • Provident Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2020 and held it in 1 quarter.
  • Provident Wealth Management's Catalyst Pharmaceutical position peaked at $4K in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on Provident Wealth Management's 13F filing for Q4 2020, filed 20 Jan 2021.